Mabion has obtained an extension of the deadline in which it is to incur at least PLN 20 million of investment expenditure in the Łódź Special Economic Zone until December 31, 2024 (earlier: December 31, 2021), the company announced.
At the same time, the deadline for completing the investment was extended from December 31, 2021 to December 31, 2024. The company’s request to change the above dates was due to the need to update the schedule of planned investments, based on the company’s current needs, according to the company announcement.
Mabion is a Polish biotechnology company that was established to market the latest generation of biotechnological drugs based on humanized monoclonal antibodies. In 2010, Mabion entered the NewConnect market, and in April 2013, the company moved to the main floor of the Warsaw Stock Exchange.
Source: Mabion and ISBnews
